InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but […]
Stock Yards Bancorp to Participate in the Janney Annual CEO Forum
LOUISVILLE, Ky., Jan. 25, 2024 (GLOBE NEWSWIRE) — Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank […]
The Bank of Bennington Expands Partnership with nCino to Include Consumer Lending
WILMINGTON, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking for the global […]
Taboola to Release Fourth Quarter 2023 Financial Results and Host Earnings Conference Call on February 28, 2024
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) — Taboola (Nasdaq: TBLA), a global leader in powering recommendations for the open […]
Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR […]
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) — Orchard Therapeutics, a global gene therapy leader, today announced the company […]
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused […]
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 25, 2024 (GLOBE NEWSWIRE) — CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the […]
eGain to Announce Fiscal 2024 Second Quarter Financial Results on February 8, 2024
SUNNYVALE, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) — eGain (NASDAQ: EGAN), a knowledge automation platform for customer engagement, will announce its […]
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
– Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable […]
